Sanofi (SNY) Teams with The Joslin Diabetes Center To Focus on New Diabetes Treatment Drugs

Article Stock Quotes (1) Comments (0)

Sanofi (NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass.

Building on Joslin's experience in diabetes research and care, the collaboration will focus on four key areas within diabetes and related metabolic disorders to identify potential new biologics or small drug candidates for the treatment of late complications of diabetes and new insulin analogs with more targeted efficacy. Additionally, research will address the challenges of insulin resistance and personalized medicine, with the overall aim of improving the lives of people living with diabetes.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference
• Microsoft (MSFT) Flat Into Reveal of Next-Gen Xbox
• Tempur-Pedic (TPX) is Now 'Tempur Sealy International'

Create E-mail Alert Related Categories

Corporate News

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?